MA32056B1 - Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene - Google Patents

Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene

Info

Publication number
MA32056B1
MA32056B1 MA33054A MA33054A MA32056B1 MA 32056 B1 MA32056 B1 MA 32056B1 MA 33054 A MA33054 A MA 33054A MA 33054 A MA33054 A MA 33054A MA 32056 B1 MA32056 B1 MA 32056B1
Authority
MA
Morocco
Prior art keywords
ibuprofen
oral medications
paracetamol
contain paracetamol
stop oral
Prior art date
Application number
MA33054A
Other languages
Arabic (ar)
English (en)
Inventor
Hartley Atkinson
Austin Kiely
Original Assignee
Wockhardt Research Center
Austin Kiely
Hartley Atkinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Research Center, Austin Kiely, Hartley Atkinson filed Critical Wockhardt Research Center
Publication of MA32056B1 publication Critical patent/MA32056B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur une suspension pharmaceutique orale contenant du paracétamol et de l'ibuprofène. L'invention porte également sur un procédé de traitement d'une douleur péri-opératoire ou postopératoire par administration à un sujet d'une quantité thérapeutiquement efficace d'une suspension pharmaceutique orale contenant du paracétamol et de l'ibuprofène.
MA33054A 2008-01-03 2010-08-02 Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene MA32056B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/000005 WO2009083759A1 (fr) 2008-01-03 2008-01-03 Suspension pharmaceutique orale contenant du paracétamol et de l'ibuprofène

Publications (1)

Publication Number Publication Date
MA32056B1 true MA32056B1 (fr) 2011-02-01

Family

ID=39521691

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33054A MA32056B1 (fr) 2008-01-03 2010-08-02 Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene

Country Status (12)

Country Link
US (1) US20110124730A1 (fr)
EP (1) EP2231138A1 (fr)
JP (1) JP2011508768A (fr)
KR (1) KR20110065417A (fr)
CN (1) CN102006867A (fr)
AU (1) AU2008345456A1 (fr)
BR (1) BRPI0821871A2 (fr)
CA (1) CA2711211A1 (fr)
MA (1) MA32056B1 (fr)
MX (1) MX2010007358A (fr)
WO (1) WO2009083759A1 (fr)
ZA (1) ZA201004650B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010125212A1 (fr) * 2009-04-27 2010-11-04 Laboratorio De Aplicaciones Farmacodinamicas, S.A. Suspension orale de lysinate d'ibuprofène
CN101991531B (zh) * 2010-11-09 2012-06-27 武汉人福药业有限责任公司 布洛芬口服混悬液及其制备方法
AU2012295397A1 (en) * 2011-08-16 2014-02-20 Merck Sharp & Dohme Corp. Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
FR2999934B1 (fr) * 2012-12-21 2015-02-20 Servier Lab Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoique et de la gomme xanthane
EP2938348A4 (fr) 2012-12-30 2016-07-27 Hadasit Med Res Service Compositions d'alginate et leurs utilisations
EP3069733B1 (fr) * 2013-11-13 2022-08-10 National Defense Education and Research Foundation Nouvelle composition d'un composé d'acétaminophène sans effet secondaire pour le foie
CN103961312A (zh) * 2014-05-26 2014-08-06 王学重 一种扑热息痛口服液及其制备方法
WO2016008546A1 (fr) 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Formulation aqueuse comprenant du paracétamol et de l'ibuprofène
DE102016203146A1 (de) 2016-02-26 2017-08-31 Ivoclar Vivadent Ag Antibakterielle Mundpflegegele
CN106361695B (zh) * 2016-08-26 2017-12-19 湖北唯森制药有限公司 一种右旋布洛芬的研磨方法及其混悬液的制备方法
WO2018192664A1 (fr) 2017-04-20 2018-10-25 Hyloris Developments Sa Procédé de préparation d'une composition à faible teneur en oxygène dissous, comprenant de l'acétaminophène, et éventuellement un ou plusieurs ains, et une composition obtenue à partir de celui-ci
CA3236068A1 (fr) * 2017-07-10 2019-01-17 Gel Cap Technologies, LLC Capsule a double forme posologique pour liberation et procedes, dispositifs et systemes pour la produire
JP7346425B2 (ja) 2018-01-11 2023-09-19 セントラス セラピューティクス 疾患を治療するためのジヒドロセラミドデサチュラーゼ阻害剤
KR101926853B1 (ko) * 2018-04-13 2018-12-07 보령제약 주식회사 약학적 조성물
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
KR102145022B1 (ko) * 2018-08-14 2020-08-14 동아제약 주식회사 이부프로펜의 현탁액 조성물 및 투여 제형
US11969400B2 (en) * 2021-03-23 2024-04-30 Kumara V. Nibhanipudi Ibuprofen for symptomatic treatment of diarrheas in HIV patients
WO2023129946A1 (fr) * 2021-12-28 2023-07-06 Zonfrillo Mark Robert Méthodes et trousses de traitement de la fièvre chez les enfants à l'aide d'une combinaison d'ibuprofène et d'acétaminophène

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0109281A1 (fr) * 1982-11-15 1984-05-23 The Upjohn Company Compositions contenant du flurbiprofen ou de l'ibuprofen
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
US5712310A (en) * 1996-06-14 1998-01-27 Alpharma Uspd, Inc. Suspension of substantially water-insoluble drugs and methods of their manufacture
MX2007000117A (es) * 2004-07-07 2007-06-15 Aft Pharmaceuticals Ltd Una composicion de combinacion.
ZA200803566B (en) * 2005-12-12 2009-10-28 Adcock Ingram Ltd Pharmaceutical compositions
US8580855B2 (en) * 2006-10-20 2013-11-12 Mcneil-Ppc, Inc. Acetaminophen / ibuprofen combinations and method for their use

Also Published As

Publication number Publication date
JP2011508768A (ja) 2011-03-17
CA2711211A1 (fr) 2009-07-09
MX2010007358A (es) 2011-05-25
US20110124730A1 (en) 2011-05-26
EP2231138A1 (fr) 2010-09-29
CN102006867A (zh) 2011-04-06
ZA201004650B (en) 2011-09-28
BRPI0821871A2 (pt) 2015-06-16
WO2009083759A1 (fr) 2009-07-09
KR20110065417A (ko) 2011-06-15
AU2008345456A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
MA32056B1 (fr) Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene
Preshaw Host modulation therapy with anti‐inflammatory agents
MA34474B1 (fr) Agonistes de gpr40
MA33295B1 (fr) Nouvelle formulation de diclofénac
AR109590A2 (es) Régimen posológico para inhibidores de comt
MA46430B1 (fr) Thérapie combinée d'agonistes de cnp à libération contrôlée
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
CZ20014289A3 (cs) Nové pouľití sloučenin jako antibakteriálních činidel
MA32692B1 (fr) Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
BRPI0516718B8 (pt) formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
MA31963B1 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
MA44764A (fr) Méthodes de traitement de patients présentant une hypercholestérolémie familiale
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
LU91933I2 (fr) 4-aminopyridine et ses dérivés
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
AR060089A1 (es) Tratamiento del dolor
ATE539747T1 (de) Verfahren und medikamente zur verabreichung von ibuprofen
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
CA2632207C (fr) Utilisation de calcitonine pour traiter la pr